Skip to main content

Hylorel Side Effects

Generic name: guanadrel

Medically reviewed by Last updated on Mar 20, 2023.

Note: This document contains side effect information about guanadrel. Some dosage forms listed on this page may not apply to the brand name Hylorel.

Applies to guanadrel: oral tablet.


Do not stop taking guanadrel suddenly without first talking to your doctor. This could cause severely high blood pressure, nervousness, and anxiety.

Use caution when driving, operating machinery, or performing other hazardous activities. Guanadrel may cause dizziness or drowsiness. If you experience dizziness or drowsiness, avoid these activities.

Use caution when rising from a sitting or lying position, especially first thing in the morning. Dizziness may occur while taking guanadrel and may result in a fall.

If you experience any of the following serious side effects, stop taking guanadrel (the active ingredient contained in Hylorel) and seek emergency medical attention or contact your doctor immediately:

Other, less serious side effects are more likely to occur. Continue to take guanadrel and talk to your doctor if you experience

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

For Healthcare Professionals

Applies to guanadrel: oral tablet.

Nervous system

The most common problems associated with guanadrel (the active ingredient contained in Hylorel) affect the nervous system. Up to 60% of patients have experienced drowsiness, fatigue, or headaches, 25% of patients experienced paresthesias or visual disturbances, and 2% experienced sleep disorders during therapy[Ref]


Cardiovascular side effects can result from excessive sympathetic blockade or a relative increase in parasympathetic tone. Orthostatic hypotension occurs in 8% to 50% of patients, some of whom experience syncope.

Unopposed or excessive parasympathetic tone can cause excessive bradycardia in rare cases. This may cause serious problems in patients with underlying sinus node dysfunction.

Peripheral edema has been reported in up to 30% of patients.

Other cardiovascular problems include chest pain in 28%, dyspnea at rest in 18%, dyspnea on exertion in 46%, and palpitations in 30% of patients. Underlying diseases may account for the relatively high incidence of some of these side effects.[Ref]

The risk of orthostatic hypotension, sometimes followed by syncope, is greatest within the first 10 minutes after dosing or early in the morning, and in hypovolemia. It is accentuated by alcohol, hot weather, or exercise--all of which are associated with peripheral vasodilation. The manufacturer recommends that guanadrel be gradually withdrawn over at least two weeks prior to administration of general anesthetics to avoid cardiovascular collapse during induction.[Ref]


Gastrointestinal side effects are also related to increased parasympathetic tone. Diarrhea has been reported in 5% to 30% of patients, some of whom discontinue therapy because of it. Constipation has been reported in up to 21% of patients. Dry mouth or parotid tenderness have been associated with the use of this drug in approximately 2% of patients.[Ref]


There is evidence that peripherally-acting antiadrenergic drugs may interfere with ejaculation by inhibiting contraction of the seminal vesicle, ampula and ductus deferens.[Ref]

Sexual impotence is a relatively common genitourinary complaint, occurring in 5% to 18% of male patients. Smaller studies, where specific questions were asked, revealed an incidence of impotence as high as 60% of male patients who were receiving a similar drug, guanethidine. Impotence appears to be reversible upon discontinuation of therapy or reduction in dosage. Urinary frequency or urgency has occurred in 30% to 50% of patients.[Ref]


Musculoskeletal cramping has occurred in approximately 20% to 40% of patients.[Ref]


1. Hansson L, Pascual A, Julius S. Comparison of guanadrel and guanethidine. Clin Pharmacol Ther. 1973;14:204-8.

2. Palmer JD, Nugent CA. Guanadrel sulfate: a postganglionic sympathetic inhibitor for the treatment of mild to moderate hypertension. Pharmacotherapy. 1983;3:220-9.

3. Finnerty FA, Jr Brogden RN. Guanadrel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs. 1985;30:22-31.

4. Owens SD, Dunn MI. Efficacy and safety of guanadrel in elderly hypertensive patients. Arch Intern Med. 1988;148:1515-8.

5. Bloomfield DK, Cangiano JL. Guanadrel and guanethidine in hypertension. Clin Pharmacol Ther. 1970;11:200-4.

6. Dunn MI, Dunlap JL. Guanadrel. A new antihypertensive drug. JAMA. 1981;245:1639-42.

7. Gore RD. Safety and efficacy of a three-drug regimen for the treatment of hypertension: hydrochlorothiazide, propranolol, and guanadrel. Clin Ther. 1983;6:86-93.

8. Bloomfield DK, Cangiano JL. Clinical experience with a new antihypertensive agent, guanadrel sulfate. Curr Ther Res Clin Exp. 1969;11:727-35.

9. Product Information. Hylorel (guanadrel). Rhone Poulenc Rorer. 2001;PROD.

10. Guanadrel (Hylorel)--a new antihypertensive drug. Med Lett Drugs Ther. 1983;25:95-6.

11. Malinow SH. Comparison of guanadrel and guanethidine efficacy and side effects. Clin Ther. 1983;5:284-9.

12. Rubenfeld S, Patten BM, Kohler PO. Effects of guanadrel on patients with thyrotoxicosis. Arch Intern Med. 1978;138:1106-8.

13. Hogikyan RV, Supiano MA. Homologous upregulation of human arterial alpha-adrenergic responses by guanadrel. J Clin Invest. 1993;91:1429-35.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.